
Jody L Green

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8031730/publications.pdf Version: 2024-02-01



LODY L CREEN

#	Article	IF	CITATIONS
1	2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clinical Toxicology, 2008, 46, 927-1057.	0.8	362
2	2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clinical Toxicology, 2011, 49, 910-941.	0.8	342
3	2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clinical Toxicology, 2009, 47, 911-1084.	0.8	327
4	2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology, 2010, 48, 979-1178.	0.8	310
5	Trends in abuse and misuse of prescription opioids among older adults. Drug and Alcohol Dependence, 2015, 149, 117-121.	1.6	144
6	Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. Western Journal of Emergency Medicine, 2013, 14, 218-226.	0.6	91
7	Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 2014, 47, 27-34.	1.5	84
8	Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and Alcohol Dependence, 2017, 175, 140-145.	1.6	39
9	Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. Journal of Pain, 2018, 19, 439-453.	0.7	39
10	Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics, 2017, 139, .	1.0	30
11	Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006–2016. American Journal of Public Health, 2018, 108, 1639-1645.	1.5	22
12	Frequency of Poison Center Exposures for Pediatric Accidental Unsupervised Ingestions of Acetaminophen after the Introduction of Flow Restrictors. Journal of Pediatrics, 2018, 198, 254-259.e1.	0.9	15
13	Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. Journal of Pain, 2016, 17, 745-752.	0.7	14
14	Adverse events associated with pediatric exposures to dextromethorphan. Clinical Toxicology, 2017, 55, 25-32.	0.8	14
15	Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. Pediatrics, 2018, 141, e20174232.	1.0	14
16	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. Journal of Substance Abuse Treatment, 2018, 84, 42-49.	1.5	13
17	Adverse events associated with diphenhydramine in children, 2008–2015. Clinical Toxicology, 2020, 58, 99-106.	0.8	13
18	Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addictionâ€Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiology and Drug Safety, 2017, 26, 1044-1052.	0.9	12

JODY L GREEN

#	Article	IF	CITATIONS
19	Medication Errors With Pediatric Liquid Acetaminophen After Standardization of Concentration and Packaging Improvements. Academic Pediatrics, 2018, 18, 563-568.	1.0	11
20	Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications. Pediatrics, 2021, 148, .	1.0	11
21	Medication Errors From Over-the-Counter Cough and Cold Medications in Children. Academic Pediatrics, 2020, 20, 327-332.	1.0	10
22	Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index–Multimedia Version (ASI-MV). Pain Medicine, 2020, 21, 1891-1901.	0.9	10
23	Changes in misuse and abuse of prescription opioids following implementation of Extendedâ€Release and Longâ€Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. Pharmacoepidemiology and Drug Safety, 2017, 26, 1061-1070.	0.9	8
24	UK survey of non-medical use of prescription drugs (NMURx) as a valuable source of general population illicit drug use data. Postgraduate Medical Journal, 2018, 94, 627-633.	0.9	8
25	Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHATâ"¢). Journal of Attention Disorders, 2021, 25, 1859-1870.	1.5	8
26	The impact of the prescription opioid epidemic on young children: Trends and mortality. Drug and Alcohol Dependence, 2020, 211, 107924.	1.6	8
27	Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children. BMC Medical Research Methodology, 2018, 18, 175.	1.4	7
28	The prescription paradox of acetaminophen safety. Pharmacoepidemiology and Drug Safety, 2016, 25, 599-601.	0.9	6
29	Flow Restrictors and Reduction of Accidental Ingestions of Over-the-Counter Medications. American Journal of Preventive Medicine, 2019, 56, e205-e213.	1.6	6
30	Understanding multiâ€pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. Pharmacoepidemiology and Drug Safety, 2019, 28, 117-121.	0.9	6
31	Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index—Multimedia Version (ASI-MV®) Network. Drug Safety, 2021, 44, 235-244.	1.4	6
32	Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit. Addictive Behaviors Reports, 2021, 14, 100376.	1.0	6
33	How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. JMIR Public Health and Surveillance, 2020, 6, e16038.	1.2	5
34	Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy. Pain Medicine, 2020, 21, 92-100.	0.9	4
35	Adverse events associated with opioid-containing cough and cold medications in children. Clinical Toxicology, 2018, 56, 1162-1164.	0.8	3
36	Trends in adverse events and related health-care facility utilization from cough and cold medication exposures in children. Clinical Toxicology, 2021, 59, 351-354.	0.8	3

JODY L GREEN

#	Article	IF	CITATIONS
37	Adverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children. Pediatric Emergency Care, 2022, 38, e100-e104.	0.5	2
38	Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study. JMIR Formative Research, 2022, 6, e16996.	0.7	2
39	Abuse-Deterrent Formulations of Prescription Opioids. JAMA Psychiatry, 2015, 72, 849.	6.0	1
40	Impact of product safety changes on accidental exposures to liquid laundry packets in children. Clinical Toxicology, 2021, 59, 392-399.	0.8	1